A-DOC can partner with clients to utilize our full TCR discovery pipeline to identify TCRs against any potential tumor antigen. The identified TCRs go through a full set of characterization assays including functional verification (e.g. T cell activation, cell killing, cytokine release, etc.), specificity, alloreactivity, and mechanism of action analysis. We can support using these TCRs in both a cell therapy format or even as a protein therapeutic (e.g. bispecific) utilizing our in-house protein science development capabilities. AmplifyBio provides a one-stop development experience because both TCR-T and TCR protein therapies can go through preclinical studies at the Amplify-SET site and can be manufactured at the A-DOC facility to ensure seamless scale-up, technical transfer, continuity in characterization approach, and IND support.